Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAM vs Melphalan Conditioning for Multiple Myeloma ASCT
NCT03570983Phase 2Unknown
- Sponsor
- Swedish Health Services
- Start
- Sep 2018
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carmustine, etoposide and cytarabine in multiple myeloma (MM) (2 arms), sponsored by Swedish Health Services. Primary endpoint: Complete Response Rate at 12 months. Status: unknown.
02
Drugs
carmustineetoposidecytarabine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03570983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03570983.